Welcome to our dedicated page for Zevra Therapeutics news (Ticker: ZVRA), a resource for investors and traders seeking the latest updates and insights on Zevra Therapeutics stock.
Zevra Therapeutics reports developments as a commercial-stage biopharmaceutical company focused on therapies for rare diseases. Recurring updates center on MIPLYFFA (arimoclomol), its U.S.-approved treatment for Niemann-Pick disease type C, including commercialization, patient access, regulatory activity and diagnostic-support initiatives tied to NPC.
Zevra news also covers financial results, pipeline programs in rare diseases such as vascular Ehlers-Danlos syndrome, and corporate actions that shape its portfolio. Recent company updates include the completed sale of the serdexmethylphenidate, or SDX, portfolio, including AZSTARYS and KP1077, as well as governance and executive-compensation announcements under Nasdaq rules.
Zevra Therapeutics has partnered with Orsini Specialty Pharmacy as the new pharmacy provider for OLPRUVA® (sodium phenylbutyrate), used to manage certain urea cycle disorders (UCDs) in both adults and children. UCDs are rare genetic conditions that hinder the body's ability to eliminate excess ammonia, which can lead to severe neurological damage if untreated. OLPRUVA® helps mitigate this risk by acting as a nitrogen scavenger to remove excess ammonia. This collaboration aims to enhance access to OLPRUVA® for patients struggling with UCDs.
Zevra Therapeutics announced positive final results from its Phase 2 clinical trial of KP1077 for idiopathic hypersomnia (IH) at SLEEP 2024. KP1077 showed significant improvements in daytime sleepiness, sleep inertia, and brain fog with good tolerance across various doses. The European Commission granted Orphan Drug Designation for KP1077 for IH treatment. Key findings include substantial decreases in ESS, IHSS, SIVAS, and BFS scores, indicating notable clinical benefits. Additionally, pharmacokinetic data suggested effective morning and nighttime dosing without significant adverse events. These findings support initiating a Phase 3 trial.
Zevra Therapeutics, Inc. (ZVRA) will participate in several investor events in May 2024, with Neil F. McFarlane, the President and CEO, presenting at conferences in New York and Boston. The company aims to engage with investors and provide updates on their rare disease therapeutics.
Zevra Therapeutics, Inc. reported its Q1 2024 financial results, including $3.4 million in revenue, increasing R&D and SG&A expenses, a net loss of ($16.6) million, and a cash balance of $52.7 million. The Company refinanced its debt, securing up to $100 million in committed capital.
Zevra Therapeutics, Inc. (ZVRA) will report Q1 2024 results on May 8, 2024. The rare disease therapeutics company will hold a conference call to discuss corporate and financial performance.
Zevra Therapeutics, Inc., a rare disease therapeutics company, releases a letter to stockholders by Neil F. McFarlane, President and CEO, highlighting key accomplishments and outlook for 2024. The letter emphasizes a patient-centric approach, team building, and progress in advancing rare disease therapies. The company's financial strength, governance enhancements, and future prospects are also discussed.
Summary not available.
Summary not available.
Summary not available.
Summary not available.